Clinical symptoms:

Increased LDL cholesterol and lipoprotein(a) are amongst the most important risk factors in the development of atherosclerosis and therefore of coronary heart disease (CHD). Cardiovascular diseases are the leading cause of death, with coronary heart disease (CHD) predominating. (Source: Fresenius brochure “DALI – Direct Adsorption of Lipoproteins”)

It has been shown that reducing atherogenic LDL cholesterol or Lp(a) prevents the progression of atherosclerotic changes and can even bring about a regression in the pathological processes.

Adsorber: DALI®

The central element of DALI® LDL apheresis is the adsorber column. The DALI® adsorber (DALI – acronym for Direct Adsorption of Lipoproteins) selectively binds LDL cholesterol and Lp(a) from whole blood. The reduction in LDL cholesterol can be tailored to suit the patient by combining different sizes of adsorber (DALI® 500, DALI® 750). The LDL cholesterol can be lowered by between 64% and 76% during treatment. (Source: Dräger et al, Eur J Clin Invest 28 (1998) 994-1002)